Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Published Results
Trial Contact Information
Registry Information

Alternate Title

Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs Phase II Treatment Completed 18 and over NCI MSKCC-03135 NCI-6444, NCT00077298, 6444

Objectives

1. Evaluate time to tumor progression in patients with irinotecan-refractory metastatic colorectal cancer treated with bevacizumab and cetuximab with or without irinotecan.
2. Evaluate objective response rate in patients treated with these regimens.
3. Evaluate overall survival of patients treated with these regimens.
4. Evaluate safety, tolerability, and adverse event profiles of these regimens in these patients.
5. Correlate a panel of molecular markers (e.g., those involved in the epidermal growth factor receptor signaling pathway, angiogenic pathway, and irinotecan metabolism) with clinical outcome in patients treated with these regimens.

Entry Criteria

Disease Characteristics:

• Histologically or cytologically confirmed colorectal cancer
  • Metastatic disease by diagnostic imaging studies



• Measurable disease
  • At least 1 unidimensionally measurable lesion with minimum lesion size at least twice the slice thickness of the imaging study used



• Refractory* to irinotecan, evidenced by clinical documentation
  • Received at least 1 prior irinotecan-containing chemotherapy regimen for metastatic disease and progressed during or within 6 weeks after completion of therapy

   [Note: *Tumor marker (e.g., carcinoembryonic antigen [CEA]) elevation alone is not considered adequate evidence of treatment failure]




• Must have received prior irinotecan according to 1 of the following schedules:
  • Weekly administration with a starting dose of 100-125 mg/m²
  • Biweekly administration (every other week) with a starting dose of approximately 180 mg/m²
  • Once every three weekly administration with a starting dose of 300-350 mg/m²



• No known brain metastases



• No prior primary CNS tumors

Prior/Concurrent Therapy:

Biologic therapy

• No prior cetuximab
• No other prior epidermal growth factor receptor-directed therapy
• No prior anticancer murine or chimeric monoclonal antibody therapy
  • Prior humanized monoclonal antibody therapy allowed
• No prior bevacizumab
• No other prior vascular endothelial growth factor-targeted therapy

Chemotherapy

• See Disease Characteristics
• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

Endocrine therapy

• Not specified

Radiotherapy

• More than 4 weeks since prior radiotherapy

Surgery

• More than 28 days since prior major surgical procedure or open biopsy

Other

• Recovered from all prior therapy
• Any number of prior standard or investigational regimens allowed
• No other concurrent investigational agents
• No other concurrent anticancer therapy
• No recent or concurrent thrombolytic agents
• No recent or concurrent full-dose warfarin except as required to maintain patency of preexisting, permanent indwelling IV catheters
• No concurrent therapeutic heparin
  • Concurrent prophylactic low-molecular weight heparin allowed
• No concurrent chronic daily aspirin (> 325 mg/day)
• No concurrent nonsteroidal anti-inflammatory medications known to inhibit platelet function
• No concurrent combination antiretroviral therapy for HIV-positive patients

Patient Characteristics:

Age

• 18 and over

Performance status

• ECOG 0-1

  OR

• Karnofsky 80-100%

Life expectancy

• More than 3 months

Hematopoietic

• WBC ≥ 3,000/mm³
• Absolute neutrophil count ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Hemoglobin ≥ 9 g/dL
• No bleeding diathesis or coagulopathy

Hepatic

• Bilirubin normal
• AST and ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN in the presence of known liver metastases)
• INR < 1.5 (for patients receiving warfarin)

Renal

• Creatinine ≤ ULN

  OR

• Creatinine clearance ≥ 60 mL/min
• No proteinuria*

 [Note: *Patients with ≥ 1+ proteinuria at baseline must have protein < 500 mg/24-hour urine collection]

Cardiovascular

• No prior stroke
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No uncontrolled hypertension
• No clinically significant cardiac arrhythmia
• None of the following arterial thromboembolic events within the past 6 months:
  • Myocardial infarction
  • Cerebrovascular accident
  • Transient ischemic attack
  • Unstable angina

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for at least 3 months after study participation
• No significant traumatic injury within the past 28 days
• No grade 3 or greater neurotoxicity
• No uncontrolled seizures
• No prior allergic reactions attributed to compounds of similar chemical or biological composition to study agents
• No prior irinotecan intolerance
• No ongoing or active infection requiring parenteral antibiotics
• No serious nonhealing active wound, ulcer, or bone fracture
• No psychiatric illness or social situation that would preclude study compliance
• No other concurrent uncontrolled illness that would preclude study participation
• No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies

Expected Enrollment

A total of 70 patients (35 per treatment arm) will be accrued for this study.

Outline

This is a randomized, multicenter study. Patients are stratified according to participating center, ECOG performance status (0 vs 1), and albumin (> 3.0 g/dL vs ≤ 3.0 g/dL). Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive cetuximab IV over 1 hour on days 1, 8, 15, 22, 29, and 36; bevacizumab IV over 30-90 minutes on days 1*, 15, and 29 OR on days 1 and 22; and irinotecan IV over 30-90 minutes (at the same dose and schedule that the patient previously received) beginning on day 1.



• Arm II: Patients receive cetuximab as in arm I and bevacizumab IV over 30-90 minutes on days 1*, 15, and 29.

 [Note: *Bevacizumab is given on day 2 (instead of day 1) of course 1, and is given on day 1 of subsequent courses.]

In both arms, courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.

Patients are followed for 3 years.

Saltz LB, Lenz HJ, Kindler HL, et al.: Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25 (29): 4557-61, 2007.[PUBMED Abstract]

Trial Contact Information

Trial Lead Organizations

Memorial Sloan-Kettering Cancer Center

Leonard Saltz, MD, Protocol chair		Ph: 212-639-2501; 800-525-2225

Registry Information
Official Title		A Randomized Phase II Study Of Bevacizumab In Combination With Cetuximab Plus Irinotecan, Or In Combination With Cetuximab Alone, In Irinotecan Refractory Colorectal Cancer
Trial Start Date		2003-12-15
Registered in ClinicalTrials.gov		NCT00077298
Date Submitted to PDQ		2003-12-16
Information Last Verified		2005-04-06
NCI Grant/Contract Number		CA08748, CM17105, CM17103, CM17101, CM17102

Back to Top